Isentress generic
Isentress is an anti-HIV drug owned by Merck Sharp Dohme. The drug contains raltegravir potassium as its active ingredient and was first given market authorization on 12 October, 2007. Isentress holds a total of 11 patents, all of which relate to its role in HIV treatment.
When will Isentress generic be available?
The generic version of Isentress is expected to become available after 30 March, 2032. This date is determined by the expiration of the last patent on Isentress, US10772888, titled 'Solid pharmaceutical compositions containing an integrase inhibitor'.
Isentress uses
Isentress is used in the treatment of HIV infection. Its active ingredient, raltegravir potassium, works by inhibiting an enzyme called HIV integrase. This inhibition prevents HIV from incorporating its genetic material into the host cell's DNA, thus slowing down or stopping the progression of the disease. Isentress can be effectively used for the treatment of HIV-1 infection.
Isentress patent expiration
Isentress is protected by a number of drug patents, the last of which, patent number US10772888, is set to expire on 30 March, 2032. This paves the way for the release of generic versions of Isentress after this date. Below are the details of the patent: